REGENXBIO Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Curran Simpson
- Full Time Employees
- 371
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9804 Medical Center Drive Rockville MD United States of America 20850
- IPO Date
- Sep 17, 2015
- CIK
- 0001590877
- Website
- regenxbio.com
- Similar Companies
- Business
- REGENXBIO Inc. (Nasdaq: RGNX) is a clinical-stage biotechnology company that develops, commercializes, and licenses recombinant adeno-associated virus (rAAV) gene therapies for the treatment of rare and debilitating diseases. The company offers a broad pipeline of product candidates across diverse therapeutic areas, including ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy via suprachoroidal delivery, RGX-121 for the treatment of Hunter syndrome (MPS II), RGX-202 for the treatment of Duchenne muscular dystrophy, and RGX-111 for the treatment of fragile X syndrome; it also provides its NAV Technology platform, which licenses proprietary rAAV vectors and capsids to partners such as AbbVie, Novartis, and Sarepta Therapeutics for use in their gene therapy programs. Founded in 2008 and headquartered in Rockville, Maryland, REGENXBIO operates primarily in the United States with a focus on ophthalmology, neurodegeneration, and metabolic diseases, targeting patients with unmet medical needs in rare genetic disorders. In recent developments, REGENXBIO reported positive 2-year data from its Phase I/II AFFINITY trial of ABBV-RGX-314 in patients with advanced wet AMD, demonstrating sustained vision preservation and reduction in anti-VEGF treatment burden. The company also advanced its RGX-121 program with FDA clearance of an investigational new drug application and initiation of the pivotal INSPIRE trial in 2024, alongside dosing the first pediatric patient. Additionally, REGENXBIO expanded its collaboration with AbbVie through a new license agreement for novel AAV capsids and strengthened its manufacturing capabilities with the completion of a state-of-the-art gene therapy facility in 2024 to support commercial-scale production.
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
REGENXBIO Announces Proposed Public Offering of Common Stock
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports
FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says
REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript
REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights